CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Thiogenesis Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Thiogenesis Therapeutics Corp
4 King St W Suite 401
Phone: (647) 846-7766p:647 846-7766 Toronto, ON  M5H 1B6  Canada Ticker: TTITTI
Business Summary
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/2023-Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Christopher M.Starr 70 3/31/2022 3/31/2022
Chief Executive Officer, Director Patrice P.Rioux 72 3/31/2022 3/31/2022
Chief Financial Officer, Company Secretary, Director Brook G.Riggins 3/31/2022 5/3/2018
Independent Director W. HoganMullally 5/3/2018 5/3/2018
Independent Director Kim R.Tsuchimoto 60 3/31/2022 3/31/2022

Business Names
Business Name
ROZ.P
TTI

General Information
Outstanding Shares: 45,495,575 (As of 4/15/2024)
Stock Exchange: CVE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024